Senators call on FDA to address ‘deluge of misleading promotions’ on social media

Sen­a­tors across both sides of the aisle are call­ing for a “swift” up­date to the FDA’s guid­ance on pre­scrip­tion drug pro­mo­tion.

Sens. Mike Braun (R-IN) and Dick Durbin (D-IL) said Wednes­day in a let­ter to FDA com­mis­sion­er Robert Califf that so­cial me­dia has giv­en rise to an “alarm­ing pro­lif­er­a­tion of dan­ger­ous and mis­lead­ing con­tent” around pre­scrip­tion med­i­cines. They point­ed to what they say are “gap­ing holes” in the FDA’s over­sight of di­rect-to-con­sumer pro­mo­tions on so­cial me­dia, and urged the agency to clar­i­fy its poli­cies around new­er plat­forms and in­flu­encers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.